Cart
sales@molnova.com
AEF0117
CAS No. 1610878-71-1
AEF0117( —— )
Catalog No. M37258 CAS No. 1610878-71-1
AEF0117, a signaling-specific inhibitor of cannabinoid receptor 1 (CB1-SSi), inhibits cannabinoid self-administration and behavioral disorders associated with THC, and can be used to study cannabis withdrawal.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 46 | Get Quote |
|
| 5MG | 61 | Get Quote |
|
| 10MG | 93 | Get Quote |
|
| 25MG | 182 | Get Quote |
|
| 50MG | 302 | Get Quote |
|
| 100MG | 484 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | 1035 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAEF0117
-
NoteResearch use only, not for human use.
-
Brief DescriptionAEF0117, a signaling-specific inhibitor of cannabinoid receptor 1 (CB1-SSi), inhibits cannabinoid self-administration and behavioral disorders associated with THC, and can be used to study cannabis withdrawal.
-
DescriptionAEF0117 a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). AEF0117 plays an important role in Cannabis use disorder (CUD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCannabinoid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1610878-71-1
-
Formula Weight436.63
-
Molecular FormulaC29H40O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)[C@@H](C(C)=O)CC4)[H])(CC=C1C[C@@H](OCC5=CC=C(OC)C=C5)CC2)[H])[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Margaret Haney, et al. Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nat Med. 2023 Jun;29(6):1487-1499.?
molnova catalog
related products
-
Org 27569
Org 27569 is a potent, selective, allosteric modulator of cannabinoid CB1 receptor.
-
Tetrahydrocannabivar...
Tetrahydrocannabivarin is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile suggests therapeutic activity in obesity, perhaps with a lowered risk of depressive side effects. Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity.
-
Drinabant
Drinabant is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.
